KCM
MCRB icon

Kennedy Capital Management’s Seres Therapeutics MCRB Stock Holding History

Kennedy Capital Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-722
Closed -$507K – 759
2015
Q4 		$507K Buy
+722
New +$475K 0.01% 699

Other funds holding MCRB

FVFI
Flagship Ventures Fund IV Cambridge, Massachusetts $382M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
FVF2
Flagship Ventures Fund 2007 Cambridge, Massachusetts $95.2M AUM
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Kennedy Capital Management's MCRB Position: Q1 2016 in Review

Kennedy Capital Management sold out of Seres Therapeutics (MCRB) in Q1 2016, closing a stake of 722 shares — an estimated $507K sold.

Kennedy Capital Management first reported a position in MCRB in Q4 2015 and held it in 1 quarter. The position peaked at $507K in Q4 2015. 76 funds tracked by Wall St. Rank hold MCRB as of Q1 2016.

  • Kennedy Capital Management reported no remaining Seres Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Kennedy Capital Management sold 722 Seres Therapeutics shares in Q1 2016, an estimated $507K.
  • Kennedy Capital Management first reported a position in Seres Therapeutics in Q4 2015 and held it in 1 quarter.
  • Kennedy Capital Management's Seres Therapeutics position peaked at $507K in Q4 2015.
  • 76 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2016.

Based on Kennedy Capital Management's 13F filing for Q1 2016, filed 13 May 2016.